论文部分内容阅读
目的：观察组胺对失血感染模型大鼠肠道细菌易位的影响。方法：从颈静脉插管放血制成单纯失血模型；经十二指肠插管灌注标准大肠杆菌液制成单纯感染模型；放血加十二指肠灌注大肠杆菌液制成失血感染模型。大鼠随机分为假手术组、单纯失血组、单纯感染组、失血感染组和不同浓度组胺治疗组共７个组。组胺治疗组分别用１×１０－４ｍｏｌ／Ｌ、１×１０－６ｍｏｌ／Ｌ和１×１０－８ｍｏｌ／Ｌ的组胺对已制成的失血感染模型大鼠进行肠道内灌注。观察模型大鼠肠系膜淋巴结和肝脏匀浆体外培养后的细菌量。结果：假手术组无细菌生长；单纯失血组和单纯感染组各有５０％大鼠组织培养细菌阳性；失血感染组全部大鼠组织出现细菌生长，该组平均组织含菌量在肝、淋巴结分别为８２．６２×１０６ＣＦＵ／ｇ和４８．８６×１０６ＣＦＵ／ｇ；组胺治疗各组的平均组织含菌量在肝、淋巴结分别为（０．６８～１．２１）×１０６ＣＦＵ／ｇ和（０．２５～１．８９）×１０６ＣＦＵ／ｇ，均明显低于失血感染组，有显著性差异（Ｐ均＜０．０５），组胺灌注各组间的平均组织含菌量无显著性差异（Ｐ＞０．０５）。结论：肠道给予小剂量组胺有保护肠粘膜屏障、抑制肠道细菌易位的作用。临床使用Ｈ２受体阻滞剂增加感染性并发症?
Objective: To observe the effect of histamine on intestinal bacterial translocation in hemorrhagic infection model rats. Methods: Bleeding from the jugular vein to make a simple blood loss model; by duodenal intubation standard Escherichia coli solution into a simple infection model; bleeding and duodenal perfusion of E. coli solution made of blood loss model. Rats were randomly divided into sham operation group, simple blood loss group, simple infection group, blood loss infection group and different concentrations of histamine treatment group, a total of 7 groups. The histamine treatment group was given intragastric perfusion with 1 × 10-4mol / L, 1 × 10-6mol / L and 1 × 10-8mol / L histamine respectively. The bacterial counts of mesenteric lymph nodes and liver homogenates in vitro were observed. Results: There was no bacterial growth in the sham-operation group; 50% of the rats in the simple blood loss group and the simple infection group were all positive for bacterial culture; the bacterial growth occurred in all the rats in the blood loss infected group, (82.62 × 106CFU / g and 48.86 × 106CFU / g). The histological average histological levels of histamine in the liver and lymph nodes were (0.68-1.21) × 106CFU / g and (0 .25 ~ 1.89) × 106CFU / g, which were significantly lower than those in the group of hemorrhagic infection (all P <0.05). There was no significant difference in the average amount of bacteria in the histamine perfusion group P> 0.05). Conclusion: Small doses of histamine given in the intestine can protect intestinal mucosal barrier and inhibit intestinal bacterial translocation. Clinical use of H2 receptor blockers to increase infectious complications?